Here's all our coverage on continuous glucose monitors (CGMs) and the future of CGM tech.
Medtronic
+3
/
Aug 11, 2025
Medtronic's new CGM built by Abbott is 510(k) pending and under FDA review, signaling major changes ahead for MiniMed insulin pumps.
Dexcom
+4
Jul 21, 2025
I speak with Dexcom about recent sensor failures and receiver recalls, how the company is responding, and what’s next—including new G7 app features and the upcoming 15-day sensor.
CGM
Jun 25, 2025
A new CGM deal moves PharmaSens one step closer to creating a fully self-contained insulin pump and CGM.
+7
Jun 20, 2025
Tandem, Beta Bionics, Sequel Med Tech, and Ypsomed are the first to announce integration plans for Abbott’s dual-analyte sensor with more expected.
Jun 16, 2025
After hearing your stories, we brought in experts—and spoke to Dexcom—to unpack what’s going on with Dexcom G7 sensor failures.
+5
Jun 12, 2025
The next wave of continuous glucose monitors promises better accuracy, longer wear time and more insulin pump integrations.
Jun 10, 2025
Dexcom's latest CGM is now supported on the Omnipod 5 iPhone App.
+1
This early pioneer was certain CGM technology would improve patient lives when others doubted her.
Future Tech
May 19, 2025
Glucotrack is working on a 3-year CGM implant that measures glucose directly from the blood.
May 14, 2025
Dexcom G7 integration is finally coming to the Omnipod 5 iPhone users.
A new frontier for metabolic health tracking — and what it could mean for the future of CGMs
Apr 21, 2025
Abbott's new app brings much needed upgrades like silence Low Alarms and control of all sensors under one umbrella.
+2
Nov 17, 2024
The 1-year implantable continuous glucose monitor makes daily diabetes management simpler - We explore what's next for the CGM tech.
Oct 29, 2024
The disposable sensor is 50% smaller and works with Medtronic's smart insulin pen.
Nov 3, 2023
The updated CGM is small, has a 30 minute warm up, and upgraded alerts—but how does it perform? Here’s what I found out after using it for over six months.
Apr 29, 2023
I ask Dexcom CEO, Kevin Sayer, your questions about Dexcom G7 and the future of continuous glucose monitor technology.
